A Detailed Analysis of the Therapeutic Apheresis Market Based on the Escalating Prevalence of Autoimmune and Hematologic Disorders, and an Increasing Emphasis on Personalized Medicine Approaches
Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 178
Report ID: PMRREP33788
The global therapeutic apheresis market is forecast to expand at a CAGR of 7.2% and thereby increase from a value of US$2.8 Bn in 2023, to US$4.6 Bn by the end of 2030.
|
Attributes |
Key Insights |
|
Therapeutic Apheresis Market Size (2023E) |
US$2.8 Bn |
|
Projected Market Value (2030F) |
US$4.6 Bn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
7.2% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
6.8% |
Therapeutic apheresis, which is alternatively spelled "apheresis" or "plasmapheresis," is a medical procedure in which certain blood components are extracted extracorporeally, separated, and returned to treat a variety of medical conditions. The aforementioned method of selectively purifying the blood is crucial in the management of autoimmune diseases, neurological disorders, and specific hematologic conditions. Therapeutic apheresis employs specialized apparatus to selectively eliminate detrimental components, thereby facilitating the patient's restoration of purified blood. This specific medical intervention has demonstrated significant efficacy in alleviating symptoms and enhancing the general state of health for individuals contending with a variety of health issues.
Numerous factors contribute to the expansion of the therapeutic apheresis market worldwide. The rising incidence of autoimmune disorders and hematologic diseases, in conjunction with technological advances in the medical field, stimulates the need for therapeutic apheresis procedures. The expansion of the market is further stimulated by the increasing awareness among healthcare professionals regarding the efficacy of apheresis in the management of various medical conditions. Furthermore, the expanding elderly demographic, which is vulnerable to various conditions treatable with therapeutic apheresis, also drives market expansion.
Additionally, the advancement of apheresis technologies is facilitated by strategic partnerships established among healthcare institutions, research organizations, and other major industry participants. Therapeutic apheresis market expansion is anticipated to persist due to a confluence of factors including medical advancements, rising disease prevalence, and collaborative endeavors within the healthcare ecosystem, as the healthcare environment continues to transform.
Perpetual Influx of Technological Innovations, and Groundbreaking Approaches
A significant catalyst for change in the therapeutic apheresis industry is the perpetual influx of technological innovations and groundbreaking approaches that reshape the terrain of treatment. New technologies emerge to improve the precision, efficacy, and scope of therapeutic apheresis procedures as medical science advances. Innovative technologies that have significantly transformed the field include membrane-based separation systems and automated apheresis devices. These advancements have enabled the extraction of blood components in a more precise and efficient manner.
The safety profile of therapeutic apheresis procedures has been substantially enhanced by these technological developments, which have reduced the likelihood of adverse events and increased patient comfort. Automated apheresis systems facilitate the consistent and regulated extraction of specific blood components, thereby enhancing the treatment process's level of precision.
In addition, the integration of sophisticated software and monitoring systems furnishes healthcare professionals with real-time feedback, empowering them to make well-informed judgments and customize remedies according to the unique requirements of each patient. By leveraging the combined capabilities of technology and therapeutic apheresis, not only are treatment outcomes enhanced, but the scope of ailments that can be efficiently managed is broadened to include neurological disorders, autoimmune disorders, and more.
Financial Constraints
Notwithstanding the notable progressions and advantages attributed to therapeutic apheresis, the industry encounters a considerable impediment originating from financial constraints. A significant financial burden is imposed on healthcare institutions and providers due to the high initial setup costs, ongoing maintenance expenses, and the requirement for specialized personnel. The substantial financial investment required for the acquisition of advanced apheresis apparatus and the enforcement of rigorous safety protocols frequently prevent smaller healthcare facilities from adopting therapeutic apheresis as part of their treatment protocols.
Extending Application Based Covering Precision Medicine
One factor driving the expansion of the worldwide therapeutic apheresis market is the increasing number of precision medicine applications for this medical intervention. In light of the ongoing transformation in the healthcare industry towards individualized and focused treatments, therapeutic apheresis presents itself as a multifaceted instrument that can effectively manage a wide range of ailments. Apheresis procedures possess the qualities of precision and selectivity that render them optimal for customizing treatments according to the unique characteristics of each patient. This presents prospects for the advancement of therapeutic strategies that are more nuanced and efficacious.
The incorporation of therapeutic apheresis into the precision medicine framework expands its applicability beyond conventional domains, including hematologic conditions and autoimmune disorders, to encompass a wide range of diseases. In the realm of precision medicine, therapeutic apheresis is progressively acknowledged as a valuable instrument, encompassing uncommon genetic disorders as well as specific forms of cancer. Therapeutic apheresis is a potentially revolutionary modality in addressing various diseases due to its capability of selectively eliminating specific substances from the blood, including pathogenic antibodies, contaminants, and disease-associated biomarkers. The broadened range of responsibilities is consistent with the increasing focus on personalized healthcare for patients, fostering prospects for cooperation among geneticists, apheresis specialists, and other fields within healthcare.
Impediments and the Intricacies Entailed in Attaining Standardization
One notable obstacle impacting the worldwide therapeutic apheresis market pertains to regulatory impediments and the intricacies entailed in attaining standardization. Achieving consistent regulatory guidelines across regions is difficult due to the heterogeneous nature of therapeutic apheresis procedures, which include a wide range of technologies and techniques. Market expansion may be impeded by regulatory framework discrepancies, which obstruct the adoption of therapeutic apheresis technologies and impede the establishment of standardized best practices. Regulatory obstacles encompass the approval and implementation of innovative apheresis technologies as well, necessitating thorough examination to guarantee both safety and effectiveness.
The worldwide market for therapeutic apheresis is undergoing a period of substantial expansion, propelled by a confluence of elements that collectively emphasize its importance in contemporary healthcare. The escalating incidence of autoimmune diseases, hematologic disorders, and specific neurological conditions on a global scale is a significant factor in this expansion. The increasing recognition of therapeutic apheresis among patients and healthcare professionals is leading to a more extensive integration of apheresis procedures into the treatment protocols of a variety of medical specialties.
Manufacturers exert significant influence on the market environment by consistently developing novel solutions to address the changing demands of healthcare providers and patients. Manufacturers and consumers engage in a dynamic interplay characterized by technological progress and market demand. Apheresis equipment manufacturers are currently emphasizing the advancement of user-friendly and more efficient models, integrating precision and automation technologies to improve the accuracy of procedures and the comfort of patients. Strategic partnerships between healthcare institutions and manufacturers additionally enable the adaptation of apheresis technologies to suit certain therapeutic purposes.
Therapeutic apheresis appears to have a bright future, as continuous research and development efforts are facilitating the emergence of innovative applications and enhanced treatment modalities. With the growing recognition of precision medicine, therapeutic apheresis is positioned to assume a more significant function by providing individualized and focused treatments. The diversification of apheresis applications to encompass oncology, neurology, and regenerative medicine presents novel opportunities for market expansion.
Furthermore, the healthcare industry is transforming due to the rise of specialized apheresis clinics, which offer specialized facilities to facilitate streamlined and effective apheresis procedures. In summary, the worldwide market for therapeutic apheresis is experiencing growth due to a confluence of factors including advancements in medicine, an increasing number of practical uses, and cooperative initiatives among stakeholders in the healthcare sector. Manufacturers and consumers are actively engaged in this dynamic environment, which fosters innovation and guarantees the ongoing development of therapeutic apheresis as a fundamental component of sophisticated medical interventions.
Supply-side Dynamics
The therapeutic apheresis market is distinguished by the participation of industry titans Asahi Kasei Corporation, Haemonetics Corporation, Terumo BCT, Inc., and Fresenius SE & Co. KGaA. Through a combination of extensive product portfolios, strategic partnerships, and a commitment to research and development, these businesses dominate the industry. Therapeutic apheresis adoption is most prevalent in North America, specifically the US, due to the continent's well-developed healthcare system and the high incidence of autoimmune and hematologic disorders. Europe, which includes the UK, and Germany, follows closely. Prominent Asian economies, notably China, and Japan, are embracing therapeutic apheresis at an accelerated rate, indicative of an expanding recognition of its advantageous attributes.
Therapeutic apheresis is extensively employed in the field of oncology within the United States, where a considerable quantity of procedures are executed to treat hematological malignancies. An apheresis is a therapeutic approach utilized in European countries such as Germany to address autoimmune neurological disorders. Japan's healthcare system incorporates therapeutic apheresis as a component of its approach to managing a range of autoimmune conditions. The ability of market leaders to penetrate regions through the dissemination of apheresis technologies is facilitated by their global reach.
The consolidation of market share is facilitated by strategic mergers and acquisitions, which strengthen the competitive advantage of major actors. Moreover, these corporations play a crucial role in advancing favorable regulatory frameworks, tackling reimbursement-related obstacles, and actively engaging in awareness campaigns to encourage the wider worldwide implementation of therapeutic apheresis. Consequently, the activities and advancements of market leaders significantly influence the course of the worldwide therapeutic apheresis industry.
What is the Largest Product Type Category?
Therapeutic Plasma Exchange to be the Leading Product Segment
Therapeutic plasma exchange (TPE) is projected to hold the most significant market share among the diagnostic apheresis segments. The extensive utilization of TPE in the treatment of diverse autoimmune disorders, neurological conditions, and hematologic maladies substantially contributes to its preeminent status. Due to its ability to effectively eliminate pathogenic substances from plasma, TPE is favored for a wide range of medical conditions, which contributes to its market dominance.
Cellular depletions are anticipated to be the therapeutic apheresis market segment with the most rapid expansion. The progression of cellular therapies, such as regenerative medicine and cancer immunotherapy, is driving the need for accurate elimination of particular cell types. Cellular depletions, which provide targeted eradication of cells implicated in a variety of diseases, are positioned for rapid expansion as personalized and cell-based therapies continue to gain traction in the therapeutic landscape. The growing acknowledgment of cellular apheresis in burgeoning medical domains establishes it as a leading candidate for rapid market growth.
Which is the Spearheading Technology-wise Segment?
Centrifugation Likely to be the Primary Category
Centrifugation is the sector within therapeutic apheresis that is anticipated to hold the most significant market share. Despite its extensive history and well-established effectiveness in segregating blood components, centrifugation technology continues to be a fundamental component of therapeutic apheresis procedures. Centrifugation, which has been extensively utilized in a range of applications such as therapeutic plasma exchange (TPE), and red blood cell exchange (RBCX), is anticipated to maintain its preeminent status in the separation of blood components on account of its adaptability and track record of success.
Although centrifugation continues to be a dominant force in the market, membrane filtration is projected to witness the most rapid expansion. The utilization of membrane-based separation systems in therapeutic apheresis is being propelled by technological advancements in this field. By its precision, compatibility with automated apheresis devices, and reduced procedural time, membrane filtration is a technology that possesses substantial growth potential.
Which is the Key Application Segment?
Oncology-based Solutions to Garner the Largest Market Value Share
It is expected that the therapeutic apheresis segment devoted to oncology will hold the most significant market share when segmented by medical specialties. The increasing prevalence of therapeutic apheresis in oncological contexts, specifically in the treatment of hematological cancers and specific solid tumors, substantially enhances the significance of this field. Therapeutic apheresis is a pivotal element in the ongoing exploration of novel treatment modalities within the domain of oncology, which contributes significantly to its market presence. The sector anticipated to experience the most rapid expansion is neurology.
Therapeutic apheresis is gaining recognition as a beneficial intervention in the treatment of neurological disorders, such as autoimmune disorders that impact the nervous system. The expanding comprehension of the function of apheresis in the field of neurology, in conjunction with progress in selectively targeting substances that are crucial to the nervous system, establishes this sector for swift growth. With ongoing research revealing novel prospects for therapeutic apheresis in the field of neuroscience, the neurology segment is positioned to experience exponential expansion within the market.
Which of the End Users is at the Forefront?
Hospitals Remain the Major End User
Hospitals are anticipated to hold the greatest market share for therapeutic apheresis. Due to the extensive range of medical services they offer, hospitals function as principal centers for therapeutic apheresis procedures. Hospitals play a crucial role in the implementation of therapeutic apheresis across numerous medical specialties due to the extensive array of specialized treatments they provide; this has contributed to their market dominance. Specialty clinics are the portion anticipated to experience the most rapid expansion.
With the increasing specialization and procedure-specificity of therapeutic apheresis, a discernible pattern emerges the formation of specialty clinics that exclusively provide apheresis services. These clinics provide a specialized setting that is both focused and efficient, to accommodate the growing need for specialized medical services. Specialty clinics are positioned for rapid expansion in the therapeutic apheresis market due to the convenience, niche expertise, and streamlined procedures they provide.
Augmenting Healthcare Expenditure to Secure the Top Spot for North America
North America is positioned to hold the largest market share of the worldwide therapeutic apheresis industry. A well-established healthcare infrastructure, substantial healthcare expenditures, and a strong emphasis on technological advancements all contribute to this dominance. A considerable concentration of prominent pharmaceutical and biotechnology firms based in the area are actively involved in research and development endeavors about therapeutic apheresis. Furthermore, the escalating incidence of autoimmune diseases, hematologic disorders, and the expansion of the elderly demographic collectively contribute to the heightened need for therapeutic apheresis procedures. The market is further strengthened in North America, specifically in the United States, due to regulatory support and a favorable reimbursement scenario.
East Asian Markets Thrive on the Back of Rapidly Rising Healthcare Consciousness
The highest rate of expansion is anticipated in the East Asian therapeutic apheresis market on a global scale. This rapid expansion is attributable to several factors, including a substantial population, rising healthcare consciousness, and an increasing incidence of chronic diseases in nations such as China and Japan. Investments in healthcare infrastructure and regional economic expansion are propelling medical technology advancements, including therapeutic apheresis. Precision medicine and personalized therapies are gaining prominence in the evolving healthcare landscape of East Asia. Therapeutic apheresis is anticipated to experience a significant increase in demand as these advanced treatment modalities increasingly incorporate apheresis procedures.
In the global therapeutic apheresis market, Fresenius SE & Co. KGaA, Haemonetics Corporation, Terumo BCT, Inc., and Asahi Kasei Corporation are all implementing diverse approaches to safeguard and optimize their market presence. An imperative approach employed by market leaders is an unwavering dedication to innovation and the ongoing improvement of their product lines. These corporations allocate substantial resources toward research and development to introduce state-of-the-art apheresis technologies. Through the implementation of more sophisticated and effective apparatus, they not only address the changing needs of medical practitioners but also establish themselves as frontrunners in providing cutting-edge therapeutic apheresis procedures.
Market leaders proactively participate in strategic collaborations and partnerships as a means to expand their market presence and sway. By establishing partnerships with healthcare organizations, research institutions, and other industry stakeholders, these businesses can remain current with technological developments, obtain valuable insights into emerging trends, and actively contribute to the creation of innovative applications. By forming strategic alliances, market leaders enhance their market position and make contributions to the expansion and recognition of therapeutic apheresis.
To attain optimal market share, it is frequently necessary to broaden one's geographical reach. Prominent entities execute strategies to expand their markets by focusing on areas characterized by a significant need for healthcare services and an increasing incidence of conditions amenable to therapeutic apheresis. This entails the formation of alliances with regional healthcare providers, the establishment of distribution networks, and the customization of marketing strategies to conform to the particular regulations and requirements of distinct areas.
New Collaboration
Terumo Blood and Cell Technologies, and Eliaz Therapeutics entered a collaborative effort in July 2022 to advance the formulation and market of an innovative therapeutic apheresis intervention for acute kidney injury (AKI).
Market Impact: The partnership between Terumo Blood and Cell Technologies and Eliaz Therapeutics, to develop a novel therapeutic apheresis intervention for acute kidney injury (AKI), is anticipated to exert a substantial influence on the international market. This advancement signifies a calculated maneuver towards broadening the utilization of therapeutic apheresis, with a particular focus on a critical medical condition such as acute kidney injury (AKI). The collaboration signifies a dedication to scientific inquiry and advancement in the domain, which may pave the way for novel opportunities in the adoption of therapeutic apheresis and strengthen its position as a multifaceted intervention capable of tackling a wide range of medical issues.
New Investment
Terumo Blood and Cell Technologies announced in June 2022 that NHS England in the United Kingdom has granted the Spectra Optia Apheresis System, an automated red blood cell exchange (RBCX) procedure utilized in the treatment of sickle cell disease, the NHS MedTech Funding Mandate (MTFM). The decision will result in an expanded adoption of Spectra Optia across various institutions in England. This will promote increased accessibility to this revolutionary treatment for patients suffering from sickle cell disease.
Market Impact: The global market is anticipated to be profoundly affected by the NHS MedTech Funding Mandate granted to the Spectra Optia Apheresis System by Terumo Blood and Cell Technologies. This system is designed to facilitate automated red blood cell exchange (RBCX) procedures for the treatment of sickle cell disease. The support of NHS England establishes Spectra Optia as the favored option for automated RBCX procedures, which may lead to greater implementation not only in the United Kingdom but also on an international scale. This advancement not only highlights the effectiveness of the system in managing sickle cell disease but also establishes a model for other healthcare systems worldwide to contemplate comparable technologies, thus impacting the wider domain of therapeutic apheresis implementation.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Procedure Type:
By Technology:
By Application:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The market is anticipated to grow at a CAGR of 7.2% during the projected period.
The therapeutic apheresis market was valued at US$2.8 billion in 2023.
The US held the largest market share in 2023.
The prominent players in the market are Asahi Kasei Medical Co., Haemonetics Corporation, Miltenyi Biotec, Cerus Corporation, Terumo BCT Inc., and Fresenius Kabi USA.
The specialty clinics segment is expected to grow at the fastest rate during the forecast period.
